Brought to you by 
Eyevance gets US rights to Nicox's Zerviate
22 Apr 2021
Executive Summary
Nicox Ophthalmics Inc. licensed Eyevance Pharmaceuticals LLC rights to commercialize its Zerviate (cetirizine) ophthalmic solution 0.24% in the US.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Eyevance gets US rights to Nicox's Zerviate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice